
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Details : HPB-092 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PHT-776
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Photys Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Photys, Polymed Sign Exclusive Deal for Phase 1-Ready IRAK4 Degrader Development
Details : Under the agreement, Polymed has granted Photys an exclusive global license to develop, and commercialize HPB-143 (PHT-776) for treating atopic dermatitis.
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : PHT-776
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Photys Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
